- Trials with a EudraCT protocol (56)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
56 result(s) found for: Interstitial Cell.
Displaying page 1 of 3.
EudraCT Number: 2022-003584-18 | Sponsor Protocol Number: KKS-307 | Start Date*: 2023-06-26 | ||||||||||||||||
Sponsor Name:Philipps University Marburg | ||||||||||||||||||
Full Title: Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia | ||||||||||||||||||
Medical condition: Progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002539-27 | Sponsor Protocol Number: IntraRenalTac | Start Date*: 2019-09-23 | |||||||||||
Sponsor Name:Oslo University Hospital – Rikshospitalet | |||||||||||||
Full Title: Association between intrarenal tacrolimus concentration and development of renal interstitial fibrosis in renal transplant recipients | |||||||||||||
Medical condition: Development of renal interstitial fibrosis in renal transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001555-14 | Sponsor Protocol Number: NBK272/1/2021 | Start Date*: 2023-01-05 |
Sponsor Name:Medical University of Gdańsk | ||
Full Title: Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseases | ||
Medical condition: fibrotic interstitial lung disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004404-19 | Sponsor Protocol Number: Acadmed18013 | Start Date*: 2014-05-07 | |||||||||||
Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment with Fostair® pMDI 200/12 on biomarkers of platelet adhesion in Patients with Idiopathic pul... | |||||||||||||
Medical condition: Idiopathic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000697-22 | Sponsor Protocol Number: FGCL-3019-095 | Start Date*: 2020-11-02 | |||||||||||
Sponsor Name:FibroGen, Inc. | |||||||||||||
Full Title: Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF). | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003751-19 | Sponsor Protocol Number: PCIA202/10 | Start Date*: 2012-01-27 | |||||||||||
Sponsor Name:PCI Biotech AS | |||||||||||||
Full Title: An open-label, single arm, multi-centre, Phase II study to evaluate the safety and efficacy of PC-A11 with superficial and interstitial laser light application in patients with recurrent head and n... | |||||||||||||
Medical condition: Recurrent head and neck squamous cell carcinoma (HNSCC) insuitable for surgery and radiotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005393-73 | Sponsor Protocol Number: ERLOPET_01 | Start Date*: 2007-09-14 | ||||||||||||||||
Sponsor Name:University Cologne | ||||||||||||||||||
Full Title: A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and t... | ||||||||||||||||||
Medical condition: The trial will be conducted in patients with non-small cell lung cancer in stage IIIb - IV | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002258-60 | Sponsor Protocol Number: UMCN-ONCO-201302 | Start Date*: 2013-08-30 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicity | |||||||||||||
Medical condition: breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019126-13 | Sponsor Protocol Number: CE-US | Start Date*: 2011-03-04 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: A PILOT, EXPLORATIVE STUDY TO IDENTIFY CONTRAST-ENHANCED ULTRASOUND (CE-US) PATTERNS THAT CHARACTERIZE ACUTE ALLOGRAFT REJECTION AND OTHER CAUSES OF ACUTE ALLOGRAFT DYSFUNCTION IN RENAL TRANSPLANT ... | |||||||||||||
Medical condition: Renal transplant | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022150-16 | Sponsor Protocol Number: Moxifloxacin Sepsis PEG | Start Date*: 2011-01-27 |
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.klinische Pharmakologie | ||
Full Title: Determination of Moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients including a pilot phase | ||
Medical condition: To evaluate feasibility of Moxifloxacin determination in septic patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-012607-26 | Sponsor Protocol Number: MIMEB | Start Date*: 2009-12-10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Cologne | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Adv... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC), first-line. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002226-13 | Sponsor Protocol Number: 2014011723 | Start Date*: 2014-11-26 | ||||||||||||||||||||||||||
Sponsor Name:Rigshospitalet | ||||||||||||||||||||||||||||
Full Title: A multimodality imaging approach for early detection and prediction of cardiotoxicity in Doxorubicin-treated patients with malignant lymphom | ||||||||||||||||||||||||||||
Medical condition: Hodgkin and non-Hodgkin lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001956-11 | Sponsor Protocol Number: 08062 | Start Date*: 2006-11-21 | |||||||||||
Sponsor Name:Celgene International SARL | |||||||||||||
Full Title: Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLC | |||||||||||||
Medical condition: Small Cell Lung Cancer (extensive stage) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000545-40 | Sponsor Protocol Number: FELZ01 | Start Date*: 2021-08-01 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – A Phase 2 Pilot Trial | ||
Medical condition: Late active or chronic active antibody-mediated rejection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002621-10 | Sponsor Protocol Number: CA209-817 | Start Date*: 2016-11-11 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with non-small cell lung cancer | ||||||||||||||||||
Medical condition: Non-Small cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) ES (Ongoing) DE (Completed) NL (Completed) GR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) CZ (Completed) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004466-19 | Sponsor Protocol Number: IFCT-2003 | Start Date*: 2021-01-07 | ||||||||||||||||
Sponsor Name:IFCT | ||||||||||||||||||
Full Title: A phase II single-group assignment, multicenter study of efficacy and safety of lorlatinib monotherapy after failure of first-line tyrosine kinase inhibitor in patients with advanced ROS1-positive ... | ||||||||||||||||||
Medical condition: advanced ROS1-positive non-small cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003867-79 | Sponsor Protocol Number: IDTX-MA-3004 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | |||||||||||||
Full Title: Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation | |||||||||||||
Medical condition: Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001275-23 | Sponsor Protocol Number: OTL-101-5(17IC04) | Start Date*: 2017-09-21 | |||||||||||
Sponsor Name:Great Ormond Street Hospital for Children NHS Trust | |||||||||||||
Full Title: Efficacy and safety of a cryopreserved formulation of autologous CD34+ haematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for human ADA gene in subjects with Severe Co... | |||||||||||||
Medical condition: Adenosine deaminase (ADA) deficiency is an inherited disorder that damages the immune system and causes severe combined immunodeficiency (SCID). Children with SCID lack virtually all immune protect... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003642-17 | Sponsor Protocol Number: OFM_DUPI_01 | Start Date*: 2018-11-23 |
Sponsor Name:Medical University Graz | ||
Full Title: AN EXPLORATORY STUDY TO INVESTIGATE THE BIOAVAILABILITY AND PHARMACODYNAMICS OF DUPILUMAB IN DERMAL INTERSTITIAL FLUID OF ATOPIC DER-MATITIS PATIENTS | ||
Medical condition: Atopic Dermatitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001573-89 | Sponsor Protocol Number: D8220C00008 | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | |||||||||||||
Medical condition: Chronic lymphocytic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) GB (GB - no longer in EU/EEA) FI (Ongoing) ES (Ongoing) FR (Ongoing) DK (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.